Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether adding high-dose-rate HDR brachytherapy can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma ESCC who have already received external beam radiotherapy EBRT, chemotherapy, and the immune therapy drug nivolumab. This phase II trial aims to see if HDR brachytherapy reduces the chance of cancer returning in the esophagus or nearby areas within 12 months and to assess safety and side effects when given after the other treatments. The study is sponsored by National Taiwan University Hospital and focuses on patients with stage III-IVB ESCC. Participants receive 1-2 sessions of HDR brachytherapy, delivered through a thin tube inside the esophagus, starting within three weeks after the first cycle of nivolumab. The brachytherapy dose ranges from 5 to 12 Gy, given in 1-2 fractions, targeting the tumor precisely while avoiding damage to normal tissues. Nivolumab is given intravenously every two weeks for several cycles alongside brachytherapy, but chemotherapy is not given on brachytherapy days. Imaging and CT scans are used for treatment planning and applicator adjustment. During the study, participants will have regular follow-up visits with imaging tests and blood samples to monitor treatment response, safety, and tumor markers. Researchers will measure the 12-month locoregional failure rate as the primary outcome and also monitor overall survival, progression-free survival, response rates, disease control, side effects, tube dependence, tumor immune activity, and circulating tumor DNA over up to 24 months. The total participation time may last up to two years with close monitoring for side effects and disease progression.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a new therapy using a patients own dendritic cells DCs and natural killer NK cells cultured in the lab to treat advanced non-small cell lung cancer NSCLC. This Phase 2 study focuses on patients with stage IIIB or IV NSCLC, including those with recurrence or progression after other treatments. The goal is to understand how these immune cells behave when given via lymph node injection and intravenous infusion and to explore their ability to fight cancer cells. Participants receive autologous dendritic cells injected into the axillary lymph nodes and natural killer cells through intravenous infusion. These cell formulations are cultured in vitro to boost their anti-cancer properties. The study assesses the safety of these treatments by monitoring reactions after administration. The trial also measures the success of cell preparation, including cell viability and tumor-killing capacity, and evaluates tumor responses using standard criteria during the 12-week treatment period. During the study, participants undergo regular monitoring including blood tests to check blood counts and liver and kidney function before cell collection. Researchers track adverse events and measure tumor response to the therapy with specified timelines up to 12 weeks. Participants must meet specific health criteria and agree to follow-up visits. The primary focus is on safety, while secondary outcomes include the effectiveness of the cultured cells against the cancer. The entire participation timeline includes screening, treatment, and evaluation phases.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how mindfulness-based programs and brain stimulation affect cognitive abilities and emotional well-being in older adults. This study focuses on understanding how these non-drug treatments might improve mental health or reduce signs of depression in late-life adults. It uses a variety of psychological, behavioral, and brain imaging tests to measure these effects. Participants will be assigned to one of four groups Mindfulness-Based Stress Reduction, Mindfulness-Based Well-Being Curriculum, Mindfulness-Based Curriculum for Insomnia, or Brain Stimulation Intervention. The study includes a baseline assessment before the treatments start and follow-up assessments to track changes after completing the interventions. Those joining the study will undergo multiple evaluations including brain scans to observe changes in brain activity and structure, psychological tests like the Wechsler Adult Intelligence Scale, and self-reported measures of mood, sleep, stress, and well-being. Continuous monitoring with smart watches will collect data on sleep and heart function over a 16-week period. The study lasts from before the intervention through one month after finishing the treatments, with detailed tracking of mental and physical health changes.
Actively Recruiting
Researchers are evaluating treatments for men with high-risk locally advanced prostate cancer, focusing on the effectiveness and safety of neoadjuvant hormone and radiation therapy followed by radical prostatectomy. This two-stage randomized trial compares neoadjuvant hormone therapy combined with radiation therapy against hormone therapy alone before surgery. The study aims to understand if adding radiation therapy before surgery improves outcomes for this condition. Participants are randomly assigned to one of two groups. The first group receives intensity modulated radiation therapy IMRT delivering 50 Gy over 25 daily fractions for 5 weeks, along with hormone therapy using Goserelin 3.6 mg injections at weeks 1, 5, and 9, followed by robotic-assisted radical prostatectomy and pelvic lymph node dissection. The second group receives only the hormone therapy injections at the same schedule before undergoing the prostatectomy. After these interventions, participants are monitored for up to 20 years. During the study, participants will be assessed for the success of salvage radiation therapy by measuring pathologic complete or near-complete response at surgery, PSA decline rates, surgical margin status, and disease staging. Researchers will also track biochemical recurrence-free survival, metastasis-free survival, prostate cancer-specific death, and overall survival over a period of up to 10 years. Follow-up visits will include regular evaluations to monitor these outcomes and ensure safety throughout the long-term study.
Actively Recruiting
This research aims to assess whether a smart wearable wristband-based care system can enhance the quality of care and physical activity levels among older adults with disabilities who receive home-based care. The study involves older adults with disabilities, their family caregivers, and multidisciplinary rehabilitation professionals to evaluate improvements in functional performance and overall care quality. Participants will use a smart wearable wristband continuously for 8 weeks to track physical activity data such as step count, activity level, heart rate, and fatigue index. The intervention includes a digital care coordination and feedback system that facilitates communication among the older adults, caregivers, and rehabilitation professionals. Outcomes are assessed before and after the intervention using standardized scales. During the study, participants undergo assessments at the start and end of the 8 weeks, including measures of daily living activities, physical activity levels, intrinsic capacity, caregiver stress, and satisfaction with the wristband system. Data on caregiver burden and service use will also be collected to analyze care quality. This trial lasts for the full 8-week intervention period with monitoring focused on changes in physical activity and care outcomes.
Actively Recruiting
Researchers are evaluating whether combining a social robot-assisted intervention with physical board games can improve social and emotional skills in children with Autism Spectrum Disorder ASD. This pilot randomized controlled trial focuses on children aged 4 to 10 years with ASD, aiming to compare the effects of using an interactive social robot during therapy versus conventional occupational therapy. The study addresses challenges these children face in recognizing emotions, regulating feelings, and interacting socially. Participants are randomly assigned to one of two 8-week programs with weekly 30-minute sessions. One group interacts with the Kebbi Air social robot using a specially designed application and modular acrylic emotion puzzle boards featuring social-emotional scenarios. A certified occupational therapist guides these sessions. The other group receives standard occupational therapy involving sensory integration equipment and social games without robotic tools or emotion puzzles. During the study, children undergo assessments before and after the intervention using parent-reported questionnaires measuring social responsiveness and emotional and behavioral functioning. Researchers monitor changes in social communication and emotional regulation. The total participation lasts 8 weeks, with outcomes measured at baseline and immediately after the intervention to evaluate the impact of the robot-assisted therapy compared to conventional methods.
Actively Recruiting
Chronic Obstructive Pulmonary Disease COPD is a major global health issue causing high morbidity and mortality, especially in low- and middle-income countries. The disease worsens with exacerbations, accelerating lung function decline and increasing death risk. Current guidelines recommend assessing lung function, exacerbation history, and symptoms to guide treatment, including triple therapy options like BreztriTrixeo BGF for patients with moderate to severe COPD who remain symptomatic despite dual therapy. The iCHOROS study aims to gather real-world data on BGFs impact on patient outcomes and quality of life in diverse populations across Latin America, Asia, and the Middle East & Africa. BGF is a fixed-dose inhaler combining budesonide ICS, glycopyrrolate LAMA, and formoterol fumarate LABA, delivered via Aerosphere technology. This observational study follows adults aged 30 to 80 who start BGF treatment as part of routine care, with no changes to standard medical management. Patients are followed for 52 weeks or until they stop BGF. Data are collected from medical records and scheduled visits at baseline, 12, 26, and 52 weeks, tracking clinical and patient-reported outcomes such as symptom scores, exacerbations, and inhaler satisfaction. Participants provide informed consent and complete questionnaires including the COPD Assessment Test CAT and modified Medical Research Council m-MRC dyspnea scale. Researchers monitor lung function tests and record exacerbation history and treatment patterns. The main goal is to assess changes in CAT scores after 12 weeks of BGF use, with additional measures at later visits. This study offers valuable insights into how BGF performs in everyday clinical settings, helping inform better COPD treatment decisions worldwide.
Actively Recruiting
Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.